Anti-Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment R58 monoclonal antibody (Clone 18F9-16)
Product Sizes
100 ug
CAC-RIK-MA-R58-100UG
About this Product
- SKU:
- CAC-RIK-MA-R58
- Application:
- IHC-Paraffin, Immunofluorescence
- translate.label.attr.clone:
- Clone 18f9-16
- Clonality:
- Monoclonal
- Extra Details:
- Background Anti-Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment R58-specific mAb 18F9-16 was cloned from mice immunized with R58 peptide [CGQILSKLR]. 18F9-16 recognizes the C-terminus cut end of LAP degradation product (LAP-D) R58 produced when latent TGF-B Beta is digested with Plasma Kallikrein. 18F9-16 is validated for IHC and IF. TGF-B Beta is produced as a pro-protein latent complex in which a 25 kDa active TGF-B Beta fragment is trapped by an N-terminal pro-peptide called Latency Associated Protein (LAP). Active TGF-B Beta is released from the latent complex in a process called the TGF-B Beta activation reaction involving a conformational change induced by binding of the latent complex to cell adhesion proteins such as thrombospondin and integrins, and/or by being cleaved by serine proteases, cysteine proteases, and MMPs in an organ and context-depending manner. Kojima and his colleagues in the Cellular Molecular Pathology Research Unit (currently, Center for Integrative Medical Sciences, Liver Cancer Prevention Research Unit), RIKEN, Japan focused on the role of serine proteases plasmin and plasma kallikrein in the release and activation of TGF-B Beta and its involvement in liver diseases. They showed that plasmin and plasma kallikrein cleave, respectively, at Lys56-Leu57 and Arg58-Leu59 within the LAP portion of the latent TGF-B Beta1 molecule. The anti-TGF-B Beta1 LAP-degradate (LAP-D) antibodies are useful for investigating the molecular mechanism of TGF-B Beta activation and its related diseases, including liver fibrosis/cirrhosis and liver degeneration. Applications Immunohistochemistry (IHC) 10 ug/mL Optimal dilutions/concentrations should be determined by the end user. Specifications Host Species mouse Form liquid, PBS (pH 7.4), 0.05% NaN3 Volume 100 ug (1 mg/mL) Specificity recognizes C-terminus cut end of LAP degradation product (LAP-D) R58 when latent TGF-B Beta is digested with Plasma Kallikrein (PLK). Antigen R58 peptide [CGQILSKLR] Clonality monoclonal (clone # 18F9-16) Isotype IgG3 Purification purified by affinity column (Protein A) from serum-free cell culture medium Conjugation none Storage condition store below -20°C (below -70°C for prolonged storage) Aliquot to avoid freeze/thaw cycles. Product Description References (1)LAP degradation product reflects plasma kallikrein-dependent TGF-B Beta activation in patients with hepatic fibrosis. Hara M, Kirita A, Kondo W, Matsuura T, Nagatsuma K, Dohmae N, Ogawa S, Imajoh-Ohmi S, Friedman SL, Rifkin DB, Kojima S. Springerplus. 2014 May 1;3:221. doi: 10.1186/2193-1801-3-221. eCollection 2014. PMID: 24877031 (2)L(59) TGF-B Beta LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. Hara M, Inoue I, Yamazaki Y, Kirita A, Matsuura T, Friedman SL, Rifkin DB, Kojima S. Fibrogenesis Tissue Repair. 2015 Sep 15;8:17. doi: 10.1186/s13069-015-0034-9. eCollection 2015. PMID: 26379781, CAC
- Host:
- Mouse
- Immunogen:
- Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment R58
- Reactivities:
- Mouse
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- -20[o]C
- Supplier:
- Cosmo Bio Ltd
- Type:
- Antibody: Monoclonal Antibody